PMID- 28306669
OWN - NLM
STAT- MEDLINE
DCOM- 20171024
LR  - 20181113
IS  - 1531-7048 (Electronic)
IS  - 1065-6251 (Print)
IS  - 1065-6251 (Linking)
VI  - 24
IP  - 4
DP  - 2017 Jul
TI  - Role of SHP2 in hematopoiesis and leukemogenesis.
PG  - 307-313
LID - 10.1097/MOH.0000000000000345 [doi]
AB  - PURPOSE OF REVIEW: SH2 domain-containing tyrosine phosphatase 2 (SHP2), encoded 
      by PTPN11 plays an important role in regulating signaling from cell surface 
      receptor tyrosine kinases during normal development as well as oncogenesis. 
      Herein we review recently discovered roles of SHP2 in normal and aberrant 
      hematopoiesis along with novel strategies to target it. RECENT FINDINGS: Cell 
      autonomous role of SHP2 in normal hematopoiesis and leukemogenesis has long been 
      recognized. The review will discuss the newly discovered role of SHP2 in lineage 
      specific differentiation. Recently, a noncell autonomous role of oncogenic SHP2 
      has been reported in which activated SHP2 was shown to alter the bone marrow 
      microenvironment resulting in transformation of donor derived normal 
      hematopoietic cells and development of myeloid malignancy. From being considered 
      as an 'undruggable' target, recent development of allosteric inhibitor has made 
      it possible to specifically target SHP2 in receptor tyrosine kinase driven 
      malignancies. SUMMARY: SHP2 has emerged as an attractive target for therapeutic 
      targeting in hematological malignancies for its cell autonomous and 
      microenvironmental effects. However a better understanding of the role of SHP2 in 
      different hematopoietic lineages and its crosstalk with signaling pathways 
      activated by other genetic lesions is required before the promise is realized in 
      the clinic.
FAU - Pandey, Ruchi
AU  - Pandey R
AD  - aDepartment of Pediatrics, Herman B Wells Center for Pediatric Research 
      bDepartment of Microbiology and Immunology cDepartment of Medical and Molecular 
      Genetics dDepartment of Molecular Biology and Biochemistry, Indiana University 
      School of Medicine, Indianapolis, Indiana, USA.
FAU - Saxena, Mallika
AU  - Saxena M
FAU - Kapur, Reuben
AU  - Kapur R
LA  - eng
GR  - R01 HL081111/HL/NHLBI NIH HHS/United States
GR  - R01 CA173852/CA/NCI NIH HHS/United States
GR  - R01 CA134777/CA/NCI NIH HHS/United States
GR  - T32 DK007519/DK/NIDDK NIH HHS/United States
GR  - R01 HL077177/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
RN  - 0 (Carrier Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 11)
SB  - IM
MH  - Animals
MH  - Carrier Proteins
MH  - Cell Transformation, Neoplastic/*genetics/*metabolism
MH  - *Hematopoiesis/genetics
MH  - Humans
MH  - Leukemia/drug therapy/*genetics/*metabolism
MH  - Molecular Targeted Therapy
MH  - Phosphorylation
MH  - Protein Binding
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & 
      inhibitors/*genetics/*metabolism
MH  - Signal Transduction/drug effects
PMC - PMC5709049
MID - NIHMS892638
COIS- Conflicts of Interest none
EDAT- 2017/03/18 06:00
MHDA- 2017/10/25 06:00
PMCR- 2018/07/01
CRDT- 2017/03/18 06:00
PHST- 2017/03/18 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
PHST- 2017/03/18 06:00 [entrez]
PHST- 2018/07/01 00:00 [pmc-release]
AID - 10.1097/MOH.0000000000000345 [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2017 Jul;24(4):307-313. doi: 10.1097/MOH.0000000000000345.